News and Announcements
MPSS Enters Into Contract For Acquisition #1
- Published August 11, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
MPSS is proud to announce the strategic plan to add scale via selected acquisition targets currently underway. The company has reached an agreement and will enter into a contract to acquire target number 1 under our scale-up plan. We anticipate that the income stream secured via this acquisition will flow from late September this year.
Furthermore, MPSS is on track to exchange EOI with our 2nd scale-up target by mid to late August 2022. The additional rent collection cash to flow from these two scale-up acquisitions will effectively double MPSS’s regular monthly income.
Due to excess capacity, MPSS is adding pure income via the completion of purchases with target 1 and is acquiring target 2 with the addition of only one existing employee. Both targets will be absorbed into MPSS existing operations and will not incur additional costs such as additional office rent and new infrastructure.
MPSS is moving ahead and we look forward to meeting with investors at the V&C conference in Singapore and discussing our unique investment opportunity which can provide investors with options to access real estate ownership directly.
Company Updates
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain
In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater. The “Meeting Room” Revelation The genesis of Elemental IV didn’t occur […]
Backed By Leading Investment Groups and Family Offices
